{"organizations": [], "uuid": "f567cfac7cea78e20d2529cd08875edb5b40dfc0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180425.html", "section_title": "Archive News &amp; Video for Wednesday, 25 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abbvies-upadacitinib-meets-primary/brief-abbvies-upadacitinib-meets-primary-and-key-efficacy-endpoints-in-phase-2b-3-rheumatoid-arthritis-study-in-japanese-patients-idUSFWN1S20Y9", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie's Upadacitinib Meets Primary And Key Efficacy Endpoints In Phase 2B/3 Rheumatoid Arthritis Study In Japanese Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.185, "site_type": "news", "published": "2018-04-25T20:43:00.000+03:00", "replies_count": 0, "uuid": "f567cfac7cea78e20d2529cd08875edb5b40dfc0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abbvies-upadacitinib-meets-primary/brief-abbvies-upadacitinib-meets-primary-and-key-efficacy-endpoints-in-phase-2b-3-rheumatoid-arthritis-study-in-japanese-patients-idUSFWN1S20Y9", "ord_in_thread": 0, "title": "BRIEF-Abbvie's Upadacitinib Meets Primary And Key Efficacy Endpoints In Phase 2B/3 Rheumatoid Arthritis Study In Japanese Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - AbbVie Inc:\n* ABBVIEâ€™S UPADACITINIB MEETS PRIMARY AND KEY EFFICACY ENDPOINTS IN PHASE 2B/3 RHEUMATOID ARTHRITIS STUDY IN JAPANESE PATIENTS\n* ABBVIE INC - SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS, WITH NO NEW SAFETY SIGNALS DETECTED\n* ABBVIE INC - SIGNIFICANTLY MORE PATIENTS RECEIVING UPADACITINIB ACHIEVED ACR50, ACR70 AND CLINICAL REMISSION AT WEEK 12 COMPARED TO PLACEBO\n* ABBVIE - IN SELECT-SUNRISE, UPADACITINIB MET PRIMARY ENDPOINT OF ACR20 ACROSS ALL DOSES AT WEEK 12 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T20:43:00.000+03:00", "crawled": "2018-04-26T20:07:23.000+03:00", "highlightTitle": ""}